The state of California currently has 945 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Providence Facey Medical Foundation, Mission Hills, California +1 locations
Conditions: Colorectal Cancer
Register for Updates
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric and GEJ cancer Cohort C: TNBC Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: The Oncology Institute of Hope & Innovation, Anaheim, California +1 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT03708224
Recruiting
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/13/2023
Locations: University of San Francisco, California, San Francisco, California
Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT03682289
Recruiting
This phase II trial studies how well Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor AZD6738 works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2022
Locations: University of California, San Francisco, San Francisco, California
Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Register for Updates
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
NCT03142204
Recruiting
This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/01/2022
Locations: UCSF Imaging Center at China Basin, San Francisco, California
Conditions: Cancer
Register for Updates
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
NCT03991741
Recruiting
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells. This is called transfer of autologous (they came from you) tumor infiltrating lymphocytes (the cells that have been grown in the laboratory. Participants getting these cell infusions will also be treated with interleu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2022
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Register for Updates
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
NCT04290897
Recruiting
This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints seen after cancer treatments.
Gender:
Female
Ages:
Between 18 years and 74 years
Trial Updated:
12/01/2022
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Register for Updates
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT04552509
Recruiting
The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatme... Read More
Gender:
Male
Ages:
All
Trial Updated:
11/03/2022
Locations: MemorialCare Saddleback Medical Center, Laguna Hills, California
Conditions: Prostate Cancer
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +1 locations
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Establish ProLung Test Measurement Collection Protocol for Future Studies.
NCT04134520
Recruiting
The purpose of this Study is to identify and test different data collection methods to determine which approaches improve the ProLung Testing procedure. Once this Study is complete, the Sponsor plans to evaluate these improvements in future follow up Validation studies that will assess device accuracy using the new measurement collection methods.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Coastal Pulmonary Associates, Encinitas, California
Conditions: Cancer , Healthy
Register for Updates
Phase I Human Analytics (HALO) Study
NCT05423860
Recruiting
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders. Additionally, the stud... Read More
Gender:
Male
Ages:
Between 45 years and 90 years
Trial Updated:
10/12/2022
Locations: Desert Medical Imaging, Indian Wells, California
Conditions: Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
Register for Updates